Format

Send to

Choose Destination
See comment in PubMed Commons below
Trends Pharmacol Sci. 2004 Aug;25(8):395-7.

Deoxyribozymes: cleaving a path to clinical trials.

Author information

  • 1GeneType Research Laboratories, 60 Hanover Street, Fitzroy 3065, Victoria, Australia. crispin.dass@genetype.com.au

Abstract

Deoxyribozymes (DNAzymes) comprise an exciting class of nucleic acid molecules that are capable of specific cleavage of target mRNA. Recent reports attest to the potential of this class of molecules in cell culture and preclinical studies, where DNAzymes exhibit the ability to silence disease-associated genes (mainly those associated with cardiovascular disease and cancer). Rigorous testing in preclinical studies is now required before this relatively new entity enters Phase I clinical trials.

PMID:
15276705
DOI:
10.1016/j.tips.2004.06.001
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center